{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-002401","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2022-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.280360+00:00","generated_at":"2026-06-27T14:38:41.291908+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Interpace appoints Vijay Aggarwal to Board, replacing Eric Lev effective Feb 1, 2022","bullets":["Eric B. Lev resigns as director effective Feb 1, 2022; no disagreement with the Company.","Vijay Aggarwal appointed to Board effective Feb 1, 2022 as Class I director.","Aggarwal will Chair Regulatory Compliance Committee and serve on Nominating & Corporate Governance Committee.","Compensation: $50k annual director fee ($40k base + $10k committee chair) plus option for 28k shares.","Aggarwal has 30+ years in diagnostics/pharma; previously CEO of Vaxigenix, President of Aureon Labs."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-002401","json":"https://secwatch.observer/filing/0001493152-22-002401.json","markdown":"https://secwatch.observer/filing/0001493152-22-002401.md","text":"https://secwatch.observer/filing/0001493152-22-002401.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222002401/0001493152-22-002401-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222002401/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T14:38:41.291908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a60f4f8a0","claim":"Vijay Aggarwal was appointed as Director at INTERPACE BIOSCIENCES, INC..","evidence_excerpt":"Dr. Vijay Aggarwal as a director to replace Mr. Lev on the Company's Board, effective February 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222002401/0001493152-22-002401-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}